{
  "id": "mhgap#referral_51739a06",
  "content": "Implementation considerations\nEML (13) includes the following oral medicines:\ny People living with psychotic disorders should be\n– haloperidol (therapeutic alternative:\ninvolved in medicine choice in a supported decision-\nchlopromazine);\nmaking process, without coercion and in line with\n– risperidone (therapeutic alternatives: aripiprazole,\nhuman rights instruments.\nolanzapine, paliperidone, quetiapine);\ny Treatment with antipsychotic medicines should\n– complementary list: clozapine.\nbe combined with psychosocial interventions (see\nother PICO questions in this module).\nPSY2. In adults with a first psychotic episode (schizophrenia) with full\nremission, how long should antipsychotic medicine be continued\nafter remission in order to allow for the best outcomes?\nRecommendation (update): Maintenance therapy with antipsychotic medicine for a minimum of\n7–12 months should be offered in adults with a first episode of psychosis\n(including schizophrenia) in remission, carefully balancing effectiveness,\nside-effects and individual preference.\nStrength of recommendation: Strong\nCertainty of evidence: Moderate\nJustification y The certainty of evidence was high for relapse at 12\ny Evidence was extracted from three systematic and 24 months and low for leaving the study early\nreviews: Ceraso et al., 2020 (75 RCTs on maintenance due to adverse events.\ntreatment with antipsychotic medicines in\nRemarks\nschizophrenia) (191); Kishi et al. 2019 (10 RCTs on",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "study",
      "referral",
      "management",
      "psychoeducation"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Referral Implementation considerations\nEML (13) includes the following oral medicines:\ny People living with psychotic disorders should be\n– haloperidol (therapeutic alternative:\ninvolved in medicine choice in a supported decision-\nchlopromazine);\nmaking process, without coercion and in line with\n– risperidone (therapeutic alternatives: aripiprazole,\nhuman rights instruments.\nolanzapine, paliperidone, quetiapine);\ny Treatment with antipsychotic medicines should\n– complementary list: clozapine.\nbe combined with psychosocial interventions (see\nother PICO questions in this module).\nPSY2. In adults with a first psychotic episode (schizophrenia) with full\nremission, how long should antipsychotic medicine be continued\nafter remission in order to allow for the best outcomes?\nRecommendation (update): Maintenance therapy with antipsychotic medicine for a minimum of\n7–12 months should be offered in adults with a first episode of psychosis\n(including schizophrenia) in remission, carefully balancing effectiveness,\nside-effects and individual preference.\nStrength of recommendation: Strong\nCertainty of evidence: Moderate\nJustification y The certainty of evidence was high for relapse at 12\ny Evidence was extracted from three systematic and 24 months and low for leaving the study early\nreviews: Ceraso et al., 2020 (75 RCTs on maintenance due to adverse events.\ntreatment with antipsychotic medicines in\nRemarks\nschizophrenia) (191); Kishi et al. 2019 (10 RCTs on Implementation considerations\neml (13) includes the following oral medicines:\ny people living with psychotic disorders should be\n– haloperidol (therapeutic alternative:\ninvolved in medicine choice in a supported decision..."
}